Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass
Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass
复制标题
DOI：
10.1002/jbmr.2932
复制
发表时间：
2017-01-01
影响因子：
6.2
通讯作者：
Libanati, Cesar
中科院分区：
文献类型：
--
作者：
Genant, Harry K.;Engelke, Klaus;Libanati, Cesar
Romosozumab是一种结合硬骨素的单克隆抗体，通过增加骨形成和减少骨吸收对骨具有双重作用，因此在骨体积调节的两个方面都具有有利的作用。在一项2期研究中，与安慰剂、阿仑膦酸钠和特立帕肽相比，romosozumab增加了低骨量绝经后妇女腰椎和全髋的DXA测量的面积BMD。在这项国际随机研究的其他分析中，我们现在描述了在接受安慰剂皮下注射的受试者亚组中，通过QCT评估的romosozumab对第12个月腰椎和髋关节体积BMD（vBMD）和BMC的影响。teriparlitazone（20 μ g，每日一次），和s.c. romosozumab（210 mg，每月一次）。在腰椎（L-1和L-2整个椎体的平均值，不包括后突）和髋关节进行QCT测量。romosozumab治疗一年后，腰椎和全髋关节的整体vBMD和BMC较基线显著增加，与安慰剂和特立哌齐相比（所有p
Romosozumab, a monoclonal antibody that binds sclerostin, has a dual effect on bone by increasing bone formation and reducing bone resorption, and thus has favorable effects in both aspects of bone volume regulation. In a phase 2 study, romosozumab increased areal BMD at the lumbar spine and total hip as measured by DXA compared with placebo, alendronate, and teriparatide in postmenopausal women with low bone mass. In additional analyses from this international, randomized study, we now describe the effect of romosozumab on lumbar spine and hip volumetric BMD (vBMD) and BMC at month 12 as assessed by QCT in the subset of participants receiving placebo, s.c. teriparatide (20 mu g once daily), and s.c. romosozumab (210mg once monthly). QCT measurements were performed at the lumbar spine (mean of L-1 and L-2 entire vertebral bodies, excluding posterior processes) and hip. One year of treatment with romosozumab significantly increased integral vBMD and BMC at the lumbar spine and total hip from baseline, and compared with placebo and teriparatide (all p